Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Episurf Medical AB (publ)    EPIS B   SE0003491562

EPISURF MEDICAL AB (PUBL)

(EPIS B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

DNB Markets - Episurf Medical: CMD 2020 highlights

share with twitter share with LinkedIn share with facebook
09/21/2020 | 04:19pm EDT

The company hosted a CMD in mid-September where management presented its long-term views. There were also several interesting presentations from KOLs in the industry, discussing the benefits for patients and doctors of the Episealer implant system. We believe Episurf Medical is moving rapidly in the right direction and that the clinical documentation is improving (and very strong). Based on the longer-term outlook, we have adjusted our fair value to SEK1.9-6.5 (1.3-3.9).

Clinical documentation key for future sales success in our view. In recent years, the documentation supporting the outcomes for the Episealer implant system has strengthened significantly. At its capital markets day in mid-September, the company focused on all aspects of its operations but, in our view, the rapidly increasing clinical documentation and presentations by KOLs in Europe were the highlights.

Long-term follow-up from first trial indicates very low revision rate - a positive in our view. In the Stålman paper (see our 8 September 2020 note), patients were followed for up to seven years; revision rates remained low and clinical outcomes high. In our view, having this type of data to support the implant system makes it much easier to convince new customers on a broader scale (and not only tech-savvy early adopters). In addition, the European multi-centre trial should be published in the autumn. As far as we understand, the data appears very compelling.

KOLs clearly positive for the implant system. Several large volume users in Europe reported their experience with the implant system, and all the features we normally consider positive were highlighted by the KOLs as bringing real value to doctors and patients.

Ambitious targets communicated. The company believes a c30% market share in its niche is reasonable over time, and highlighted that the target is c15% market share in the US some three years post-launch (estimated for c2024). Given the alternatives available today, we believe this is realistic, but the question of a potential partner in the US market remains. We believe the choice of actual partner should affect the likelihood of reaching that target in the specified time-frame.
Forecasts updated and fair value adjusted. We believe the market-share targets are ambitious but doable, especially with the strong clinical outcome data seen lately. Based on the new clinical data seen this year, we have increased our longer-term market-share assumptions and as a result increased our fair value to SEK1.9-6.5.
Click here to view full report (https://www.dnb.no/seg-fundamental/fundamentalweb/GetReports.aspx?file=CMPSP_162581.pdf&Sid=1-7XT0MIJ)
Best regards 
__________________________________________________
Patrik Ling | DNB Markets | Equity Research | Senior Analyst Healthcare
DNB Bank ASA
Regeringsgatan 59 | Stockholm | Sweden
 

https://news.cision.com/episurf-medical-ab/r/dnb-markets---episurf-medical--cmd-2020-highlights,c3200215

https://mb.cision.com/Main/14661/3200215/1308984.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English


Stocks mentioned in the article
ChangeLast1st jan.
DNB ASA -0.23% 128.25 Delayed Quote.-21.95%
EPISURF MEDICAL AB (PUBL) 1.34% 1.942 Delayed Quote.65.64%
share with twitter share with LinkedIn share with facebook
All news about EPISURF MEDICAL AB (PUBL)
10/26DNB MARKETS - EPISURF MEDICAL :  Clinical data strengthens the case
AQ
10/26EPISURF MEDICAL : First Episealer® surgery performed in Asia
AQ
10/23EPISURF MEDICAL : Interim Report 1 July - 30 September 2020
AQ
10/15EPISURF MEDICAL : enters into a distribution agreement for additional markets in..
AQ
10/14EPISURF MEDICAL : Members of the Nomination Committee for Episurf Medical's Annu..
AQ
10/08EPISURF MEDICAL : Episealer® publication available online
AQ
10/01EPISURF MEDICAL : First Episealer® surgery performed in the US
AQ
09/30EPISURF MEDICAL : Results from Swedish multi-centre clinical trial with follow-u..
AQ
09/25EPISURF MEDICAL : Upping Long-Term Sales
AQ
09/21DNB MARKETS - EPISURF MEDICAL : CMD 2020 highlights
AQ
More news
Financials
Sales 2020 6,00 M 0,67 M 0,67 M
Net income 2020 -73,0 M -8,17 M -8,17 M
Net cash 2020 81,0 M 9,07 M 9,07 M
P/E ratio 2020 -4,85x
Yield 2020 -
Capitalization 359 M 40,2 M 40,1 M
EV / Sales 2020 46,3x
EV / Sales 2021 30,0x
Nbr of Employees 25
Free-Float 89,1%
Chart EPISURF MEDICAL AB (PUBL)
Duration : Period :
Episurf Medical AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EPISURF MEDICAL AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 2
Average target price 4,00 SEK
Last Close Price 1,94 SEK
Spread / Highest target 106%
Spread / Average Target 106%
Spread / Lowest Target 106%
EPS Revisions
Managers
NameTitle
Pål Ryfors Chief Executive Officer
Dennis D. Stripe Chairman
Katarina Flodstrom Chief Operating & Regulatory Officer
Veronica Wallin Chief Financial Officer
Leif Erik Sigfrid Ryd Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
EPISURF MEDICAL AB (PUBL)65.64%40
STRYKER CORPORATION-2.17%76 980
SMITH & NEPHEW PLC-25.81%15 715
VENUS MEDTECH (HANGZHOU) INC.105.47%4 044
WRIGHT MEDICAL GROUP N.V.0.39%3 967
INSPIRE MEDICAL SYSTEMS, INC.66.95%3 216